Infliximab does not increase colonic cancer risk associated to murine chronic colitis

doi:10.3748/wjg.v22.i44.9727

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 22, Issue 44

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8811)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series.

Item

Count

PDF

487

WORD

341

HTML

4653

Figures (1-3)

302

Sum=5783

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1084

Download

1944

Sum=3028

Nov 28, 2016 (publication date) through Feb 8, 2025

Times Cited of This Article

Times Cited (8)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Gastroenterol. Nov 28, 2016; 22(44): 9727-9733
Published online Nov 28, 2016. doi: 10.3748/wjg.v22.i44.9727

Full Size Figure Download Figure

Figure 2 Effect of Infliximab on colonic cancer lesions associated to chronic colitis in mice. A: Macroscopic lesion number in Infliximab treated mice compared with controls; B: Microscopic colon lesions classified as carcinoma (K), high grade-dysplasia adenoma (HGA) and low grade-dysplasia adenoma (LGA); C: Macroscopic colon lesions (Infliximab treated on the left and controls on the right); D: Histological photos of carcinoma (K), high grade-dysplasia adenoma (HGA) and low grade-dysplasia adenoma (LGA).

Citation: Lopetuso LR, Petito V, Zinicola T, Graziani C, Gerardi V, Arena V, Caristo ME, Poscia A, Cammarota G, Papa A, Cufino V, Sgambato A, Gasbarrini A, Scaldaferri F. Infliximab does not increase colonic cancer risk associated to murine chronic colitis. World J Gastroenterol 2016; 22(44): 9727-9733
URL: https://www.wjgnet.com/1007-9327/full/v22/i44/9727.htm
DOI: https://dx.doi.org/10.3748/wjg.v22.i44.9727